Literature DB >> 8746624

Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1.

I Dodd1, D E Mossakowska, P Camilleri, M Haran, P Hensley, E J Lawlor, D L McBay, W Pindar, R A Smith.   

Abstract

We have developed a simple expression, isolation, and folding protocol for an SCR oligomer comprising the first three SCRs of complement receptor Type 1 (C3b/C4b receptor, CD35). A T7 RNA polymerase expression system in Escherichia coli was used to express the oligomer as inclusion bodies. The oligomer was recovered from solubilized inclusion bodies using batch adsorption on SP-Sepharose. The oligomer was folded by one-step dilution in 20 mM ethanolamine/1 mM EDTA supplemented with 1 mM GSH/0.5 mM GSSG. The folded material was processed to a concentrated (> 20 mg/ml), usable product of greater than 98% purity using a combination of ultrafiltration, ammonium sulfate treatment, hydrophobic interaction, and size-exclusion chromatography. The yield of folded material varied between 6 and 15 mg/liter culture. The oxidation states of the 12 cysteine residues in SCR(1-3) were identified by HPLC of peptide fragments from a tryptic digest using dual UV/fluorescence detection, collection of selected peaks, and N-terminal sequencing. This methodology confirmed the expected location of disulfide bridges. Equilibrium and velocity sedimentation studies are interpreted in terms of a single sedimenting species with molecular weights of 21,629 and 21,063 by these respective techniques. These values compare to the predicted molecular weight, from amino acid composition, of 21,817. The hydrodynamic properties of the molecule indicate that it is asymmetric with an axial ratio of 1:5.2 or equivalent dimensions of 21 x 110 A. SCR(1-3) has an unusual CD spectrum exhibiting a broad maximum at 220-230 nm and a minimum at 190 nm. There was little evidence of classical secondary structure. The product exhibited concentration-dependent inhibition of complement-mediated lysis of sensitized sheep red blood cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8746624     DOI: 10.1006/prep.1995.0003

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  10 in total

1.  Tissue distribution and functional analysis of Sushi domain-containing protein 4.

Authors:  Zhidan Tu; Mark Cohen; Hong Bu; Feng Lin
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

Review 2.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

3.  Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.

Authors:  Geoffrey Gifford; Vivian P Vu; Nirmal K Banda; V Michael Holers; Guankui Wang; Ernest V Groman; Donald Backos; Robert Scheinman; S Moein Moghimi; Dmitri Simberg
Journal:  J Control Release       Date:  2019-04-08       Impact factor: 9.776

4.  Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins.

Authors:  Georgia Sfyroera; Madan Katragadda; Dimitrios Morikis; Stuart N Isaacs; John D Lambris
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

5.  Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.

Authors:  Deborah A Fraser; Claire L Harris; Richard A G Smith; B Paul Morgan
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

6.  Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.

Authors:  Jennifer White; Petra Lukacik; Dirk Esser; Michael Steward; Naomi Giddings; Jeremy R Bright; Sarah J Fritchley; B Paul Morgan; Susan M Lea; Geoffrey P Smith; Richard A G Smith
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

7.  Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy.

Authors:  Julian R Pratt; Miriam E Jones; Jun Dong; Wuding Zhou; Paramit Chowdhury; Richard A G Smith; Steven H Sacks
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

8.  Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.

Authors:  Adam Badar; Sarah DeFreitas; James M McDonnell; Norhakim Yahya; David Thakor; Reza Razavi; Richard Smith; Steven Sacks; Gregory E D Mullen
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

9.  A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.

Authors:  Theodoros Kassimatis; Anass Qasem; Abdel Douiri; Elizabeth G Ryan; Irene Rebollo-Mesa; Laura L Nichols; Roseanna Greenlaw; Jonathon Olsburgh; Richard A Smith; Steven H Sacks; Martin Drage
Journal:  Trials       Date:  2017-06-06       Impact factor: 2.279

10.  APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.

Authors:  Fang Xiao; Liang Ma; Min Zhao; Richard A Smith; Guocai Huang; Peter M Jones; Shanta Persaud; Attilio Pingitore; Anthony Dorling; Robert Lechler; Giovanna Lombardi
Journal:  Br J Pharmacol       Date:  2016-01-11       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.